Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy - OncologySTAT
Links shared publicly online about this topic.
- 1,945total visits
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy - OncologySTAT
J Clin Oncol. 2009 Jun 6; Epub ahead of print - MRD assessment by real-time qualitative PCR, combined with preemptive arsenic trioxide, markedly improved relapse rates.
View full resource at oncologystat.com
Tags: Leukemia, Disease and Condition, disease
Most Recently Shared on June 24, 2009 at 8:57 pm By:
Story of the Week: Preemptive Therapy Based on Real-Time Quantitative PCR Improves Relapse-Free Survival in APL http://tinyurl.com/nqmp7v
Advertisement
